× Key messages Background Findings Perspectives Expert commentary
Home Font size Night/Day Mode Index


What does this study add?

  • AHCL therapy improved mean HbA1c from 7.5% to 7.0%.
  • Almost twice as many patients achieved an HbA1c≤7.0% with AHCL therapy vs. baseline.
  • More participants achieved a TIR70-180 ≥70%.
  • This further increased for all groups at the basal target set point of 100 mg/dL.
  • There were no events of diabetic ketoacidosis, severe hypoglycemia during the study phase, serious or unanticipated adverse device effects.